Painful crisis is the commonest and most distressing clinical manifestation of sickle cell anaemia (SCA), thus prompt and adequate analgesia should be provided to ameliorate the suffering of the patient. Pentazocine is a potent opioid analgesic with mixed receptor activities commonly used in the management of pain in SCA patients. Its abuse among SCA patients has remained a daunting challenge in medical practice worldwide, especially in developing economies like ours. However, reports on opioid abuse or dependence among SCA patients in our environment are inexistent. This report sets out to highlight the addictive potential of pentazocine and the complications associated with its abuse in SCA patients. We report a case of a 40-year-old known SCA female with a five-year history of excessive use of parenteral pentazocine. She commenced self-injection of pentazocine following a previous admission in a private hospital on account of bone pain crisis. Other analgesics such as diclofenac, ibuprofen, piroxicam and tramadol were not efficacious in alleviating her excruciating pain but the administration of parenteral pentazocine provided her with quick and complete relief, hence the beginning of her dependency. She had a hankering desire to use the drug which she used on daily basis. Initially, she injected 30-60mg (1 -2 ampules) of pentazocine per day but in the last one month before presentation in our facility, she increased the dose of the drug to 270mg (9 ampoules) daily. She developed multiple cutaneous and musculoskeletal complications. A diagnosis of pentazocine dependence in a sickle cell anaemia patient was made. She was admitted and jointly managed by the Haematology, Orthopaedic and Mental Health Teams. We hereby advocate effective sensitization of healthcare providers, SCA patients, their caregivers and the society at large about the risks and complications of pentazocine abuse. This is to espouse the fervid need to exercise caution with pentazocine prescription and use. As much as possible, oral formulations, when deemed necessary, should be recommended since most of the observed physical complications occurred apparently as a result of parenteral administration of the drug. Lastly, pentazocine should be categorized as a controlled drug with stringent measures in place to regulate its sales in our environment.
INTRODUCTION
Sickle cell anaemia (SCA) is a form of sickle cell disease (SCD), which is a heterogenous group of autosomal co-dominant qualitative haemoglobin disorder [1] . SCA is the most prevalent and severe form and results from inheritance of two homologous haemoglobin S (Hbs) alleles, affecting 60% to 70% of people with SCD. Other SCD genotypes include haemoglobin SC disease, haemoglobin SD disease, sickle cell beta thalassaemia among others [1, 2] .
SCA is a chronic, monogenic disorder of increasing global health importance with highly diverse clinical manifestations traceable to its peculiar pathologic nature [3] . It is marked by acute exacerbations of bone and visceral pain secondary to vaso-occlusion and ischaemia. The pain is characteristically excruciating and debilitating, and represents an important cause of frequent hospital visits and admissions [4, 5] . Elander et al [6] , in their study among SCA patients who were substance dependent, found that pain-related symptom constituted 88% of all symptoms. Similar findings have been reported by other workers [7, 8] . Fluid therapy and analgesia are essential aspects of sickle cell pain crisis management [9] . Choice of analgesia depends on the severity of the pain and the patient's prior analgesic needs or history and usually includes opioids or non-steroidal anti-inflammatory drugs (NSAIDs) either alone or in combination [10] . The protracted use of NSAIDs in SCA patients is strongly discouraged because of the risk of NSAID -induced vasoconstriction of the renal vasculature and consequent chronic kidney disease coupled with the already existing background propensity to develop nephropathy [11, 12] . In SCA, NSAIDs are usually prescribed in the management of mild pain while moderate to severe and chronic pain often require the opioids [9, 12] . In difficult cases, where pain is unremitting after 48 hours of adequate analgesia, exchange blood transfusion is the therapy of choice [9] . Other treatment modalities for intractable pain in SCA include nerve block, physiotherapy, orthopaedic intervention or surgery, and cognitive behaviour therapy [9, 13] . The clinician has the duty to ensure prompt and effective pain control and in the same vein should be wary of exceeding the medical needs of the patients [9] .
Pentazocine, a synthetic opioid analgesic of the benzomorphan family [14] , is usually the first choice opioid in managing acute and chronic painful episodes in sickle cell anaemia patients, followed by tramadol, dihydrocodeine and morphine in that order [9, 15] . Pentazocine lactate, the intramuscular/intravenous injectable form is readily available in Nigeria and other African countries and is widely used for pain relief. It has a mixed receptor action and acts by binding to kappa, mu and delta (,µ & ) receptors in the sensori-neural system and other tissues [14, 16] . It is worthy of mention that pentazocine was introduced in 1967 to address the problem of lack of a potent analgesic that had no unsavoury effect such as drug dependence, a goal that has been practically unachieved. Pentazocine has an estimable analgesic action although its prolonged parenteral use or abuse has been associated with several adverse effects including, skin fibrosis, ulceration, abnormal pigmentation, fibrous myopathy and contractures [17, 18, 19] . In the current world health organization (WHO) analgesic ladder and guidelines in pain control, pentazocine has been omitted due to its tendency to cause dependence and the aforementioned deleterious effects as well as other notable ones [20, 21] .
It is interesting to note that phenotypic and genotypic variations exist among different individuals with SCA and even occur over time in the same patient [3] .
This may hamper fervent efforts at achieving adequate analgesia over time with regards to management of sickle cell pain crisis.
Pentazocine abuse refers to a psychological dependence on pentazocine with associated craving, lack of capacity to limit or stop its consumption, the emergence of a withdrawal syndrome during cessation and the compulsive use aimed at achieving euphoric effects despite obvious harm [22] . This addiction may lead to devastating consequences associated with unconscionable craving in spite of adequate dosing and pain control with other analgesics. The use of pentazocine as a sole agent in the treatment of chronic pain has been identified as an important cause of addiction [23] .
Cases of pentazocine abuse have been reported worldwide. The menace has also been observed among sickle cell anaemia patients in Nigeria [24, 25] .
Many patients with SCA already have a poor quality of life and low life expectancy [9] . Thus, unwholesome practice such as pentazocine abuse could exacerbate the bleak clinical outlook in SCA patients in a developing country like ours where access to appropriate and adequate healthcare services is suboptimal. In our environment, a significant number of these patients, purchase the drug "over the counter". Efforts have been made in some countries to exterminate the abuse of pentazocine. The intervention strategies include classifying pentazocine as a controlled drug to prevent unwarranted access to the drug and the production of pentazocine brands containing naloxone to counteract the addictive property [21, 22] .
In spite of the foregoing, the cases of pentazocine abuse in Nigeria, especially in SCA patients, are increasing and no tangible measures have been put in place to rein the unnerving trend. Moreover, there are no reports of pentazocine abuse as well as its associated morbidities in SCA patients in our locality probably because of low index of suspicion and due to patients' unwillingness to volunteer such information. This report is therefore designed to highlight some of the physical complications and socio-economic challenges associated with pentazocine abuse in SCA patients as well as evaluate the necessity for stringent legislation to regulate the procurement of the drug in our country.
CASE REPORT
A 40-year -old unemployed university graduate residing in Uyo, Nigeria presented to the Haematology clinic, University of Uyo Teaching Hospital with a history of recurrent fever, difficulty in breathing, chest pain and painful swollen arms and thighs. She was a known sickle cell anaemia patient and had an intense desire to use pentazocine which she injected intramuscularly (occasionally intravenously) herself on daily basis. She started abusing pentazocine 5 years prior to presentation, following a bone pain crisis for which intravenous pentazocine (first ever dose) was prescribed by her family physician for pain relief. Then she received 30mg of pentazocine daily for 5 days and she reported having profound relief after receiving the injection with all her pain disappearing. After the treatment, she began to abuse the medication by self-administration; she injected the drug into her buttocks, upper limbs, lower limbs, abdomen, the chest and neck. In the last 1 month, she increased the dose of the drug from initial 30-90mg daily to 270mg daily.
Initially, she spent about one thousand naira (about $3.00) per day to purchase pentazocine from pharmacies without doctor's prescription which increased to about nine thousand naira (about $25,000) with increasing amount of pentazocine (30mg to 270mg). To sustain her drug using habit, she sourced money by stealing from her mother, or lying to strangers, friends and her three older siblings who reside in London to give her money for other purposes. She mismanaged the funds given to her and found herself unable to take care of her basic needs such as buying clothing, shoes and consistently depended on her mother and siblings for her daily needs. She had previously experienced the euphoric effect of pentazocine when it was first used by her family physician to alleviate her pains. She enjoyed this effect and was always looking forward to the next dose. Whenever she did not use the drug, she would be dysphoric, restless and insomniac. This was a distressing experience for her, so she ensured that the drug was always handy. She had to use the drug on a daily basis to be able to have a pleasant day despite evidence of infection at injection sites which sometimes required prolonged antibiotic therapy, incision and drainage.
She was diagnosed with SCA at the age of 2 years, and was neither compliant with proguanil hydrochloride, folic acid and other prescribed medications nor regular with follow-up visit. Prior to her abuse of pentazocine, she experienced crisis about 8-9 times annually, which was relieved with tramadol or diclofenac.
The patient was admitted 2 months ago on account of similar complaints for 2 weeks at our facility and comanaged by the Haematologist, Orthopaedic Surgeon and Mental Health Physician. She was discharged to continue treatment as an outpatient with weekly psychological sessions but was not abstinent and did not keep follow-up clinic appointments.
She was the only SCA patients in a monogamous setting of four children. Management of these complications usually require hospital admission, antibiotic therapy, daily wound dressing, hydroxyurea therapy, zinc therapy, skin grafting, hypertransfusion and automated red cell exchange [24] [25] [26] [27] . It is to be noted that the patient was offered these therapeutic options but she did not make the best use of them owing to her infrequent hospital visit and noncompliance with treatment.
Massive lymphedema of the upper and lower limbs was one of the most striking and cosmetically disfiguring physical complication observed in the patient. This could have resulted from blockade of the lymphatic drainage by inflammation, myopathy, ulceration, scarring and fibrosis following repeated injection of pentazocine. This is one complication that has been extensively documented in other related works [17-19, 24, 25, 27, 28] . Systematic review of published literature shows filariasis to be the most common cause of secondary lymphedema in the developing world while cancer therapy is the leading cause of the condition in developed climes [27] [28] [29] . Regrettably, parenteral pentazocine abuse appears to be the most frequent cause of lymphedema in patients with SCA in our country [24, 25, 28] . There is no cure for lymphedema currently. Available therapies are essentially palliative and include physiotherapy and use of bandages to manage and reduce the swelling [30] . Surgical interventions such as volume reducing surgery and lymphatic microsurgery are not routinely performed [31] .
Some form of fibrous myopathy was noted in our patient. However, we did not confirm the diagnosis using biochemical, radiological and histological investigations, but history and examination findings were highly suggestive.
This complication has been grossly underreported generally in spite of its notoriety of being a common sequela of prolonged parenteral pentazocine abuse. The underlying pathogenetic mechanism is not well elucidated but easy precipitation of pentazocine in the neutral or slightly alkaline pH of extracellular fluid with attendant inflammation and fibrosis may play a role [27] . The fibrous myopathy contributed to the contractures and deformities observed in the patient. The contractures accounted for the fixed flexion and extension in some of her joints resulting in impaired movement and gait abnormality.
Management of these complications comprises detoxification and withdrawal of pentazocine, use of corticosteroids or nonsteroidal anti-inflammatory drugs, collagenases, physiotherapy, myotomy or myectomy and muscle lengthening procedures [18] . However, there may be permanent disability particularly if the affected muscles are fibrotic and non-functional [32] .
The patient was single and unemployed as earlier stated and we believe that her SCA status may have been responsible for these. The major physical complications of pentazocine abuse may make her unattractive to a prospective spouse or employer. Moreover, her unmarried status may engender a vicious cycle of pentazocine abuse because of the absence of a partner's restraining influence. On the other hand, the unpredictable and frequent illness episodes and hospital visits and admissions may significantly contribute to her inability to keep a relationship or job.
Astoundingly, the patient had high daily doses of pentazocine injections for a long period. The maximum dose of pentazocine that she injected daily was 270mg (9 ampoules). She spent an insane amount of money to sustain the unhealthy habit. The highest amount she ever expended monthly on purchase of the drugs was noted to be NGN 270,000. In order to have a steady supply of the drug, the patient told a lot of lies to get money from family members, friends and even strangers. She, however, denied ever engaging in unchaste relationships or anti-social activities in return for money though she admitted to using forged prescriptions and sometimes did not present prescription papers at all to access the drug from pharmacies and drug stores. These illicit transactions are possible because there has been apparently no stringent regulations on procurement of the drug, no effective system to verify drug prescriptions and no austere punishment or penalties for erring healthcare providers and their clients. Unfortunately, pentazocine is readily available as over-the-counter drug in our society where it is sold in almost every drug store or pharmacy illegally without medical prescription. In view of this, it is plausible to posit that the abuse of injectable pentazocine may be more common 
